|1.||Nehlig, Astrid: 2 articles (10/2011 - 01/2011)|
|2.||Fernandes, Maria José da Silva: 2 articles (10/2011 - 01/2011)|
|3.||Rosim, Fernanda Elisa: 2 articles (10/2011 - 01/2011)|
|4.||Persike, Daniele Suzete: 2 articles (10/2011 - 01/2011)|
|5.||Rybak, Leonard P: 2 articles (01/2010 - 05/2004)|
|6.||Ramkumar, Vickram: 2 articles (01/2010 - 05/2004)|
|7.||von Heijne, M: 2 articles (01/2001 - 07/2000)|
|8.||Hao, J X: 2 articles (01/2001 - 07/2000)|
|9.||Sollevi, A: 2 articles (01/2001 - 07/2000)|
|10.||Xu, X J: 2 articles (01/2001 - 07/2000)|
10/24/1997 - "Anaesthetized dogs were randomized to a control group subjected to 40-min occlusion of a diagonal branch of left anterior descending coronary artery (LAD) followed by 1-h reperfusion, or a preconditioned group (PC) in which the same period of sustained ischemia and reperfusion was preceded by a single cycle of IP (5-min occlusion of the same LAD branch and 10-min reperfusion), or to PIA group in which R-PIA infusion into the same branch of LAD (0.4 microg/kg per min during 5 min) was followed by 10 min of perfusion prior to sustained ischemia-reperfusion. "
06/01/1996 - "Agonist-induced receptor down-regulation was not found after perfusion with R-PIA in low-flow ischemia. "
12/07/1992 - "These results indicate that the depressive action of R-PIA during ischemia results from various effects which are not restricted to a local action on the hippocampus."
05/01/1991 - "R-PIA had no effect on cerebral metabolism before ischemia. "
12/01/1992 - "It can also be deduced that the antinociceptive effects of R-PIA after intrathecal injection are not a consequence of spinal ischemia and that disturbances in local blood flow cannot be expected to constitute a neurotoxic factor."
|2.||Ocular Hypertension (Glaucoma, Suspect)
05/01/1992 - "In New Zealand White rabbits, the topical administration of 500 micrograms of the relatively selective adenosine A1 receptor agonist R(-) phenylisopropyladenosine (R-PIA) produced a biphasic response in IOP in the ipsilateral eye: an initial ocular hypertension (3.5 +/- 1.4 mm of Hg) at 0.5 hour, followed by significant reduction in IOP (5 to 8 mm of Hg) from 2 to 6 hours postadministration. "
06/01/1997 - "A single unilateral topical application of R-PIA (20-250 micrograms) or CHA (20-500 micrograms) produced ocular hypertension (maximum rise = 4.9 or 3.5 mmHg) within 30 min, followed by ocular hypotension (maximum fall = 2.1 or 3.6 mmHg) from 2-6 hr. The relatively selective adenosine A2 antagonist 3,7-dimethyl-1-propargylxanthine (DMPX, 320 micrograms) inhibited the early hypertension, without influencing the hypotension. "
|3.||Mononeuropathies (Mononeuritis Multiplex)
02/28/1997 - "The aim of the present study was to investigate the intrathecal (i.t.) action of a selective A1-adenosine receptor agonist, R-phenylisopropyl adenosine (R-PIA), on tactile withdrawal thresholds in a rat model of mononeuropathy produced by sciatic chronic constriction injury (CCI). "
07/29/1996 - "The aim of the present study was to investigate the effect of intravenous or intrathecal (i.t.) administration of R-phenylisopropyladenosine (R-PIA), a selective A1 adenosine receptor agonist, on spontaneous scratching behaviour, a phenomenon presumably related to pain in a mononeuropathy model (sciatic nerve ligation) in rats. "
12/01/1998 - "The anti-allodynic effect of R-PIA was maintained for 6-7 days with twice-daily administration and was reduced thereafter, particularly with respect to cold allodynia. "
12/01/1998 - "IT R-PIA completely alleviated allodynia-like behaviors to mechanical and cold stimuli in spinally injured rats. "
02/28/1997 - "R-PIA (1-10 nmol i.t.) induced a dose-dependent suppression of the tactile allodynia without producing impairment of motor function. "
09/01/2010 - "Intrathecal application of R(-)N6-(2phenylisopropyl) adenosine (R-PIA; 10 nmol), a selective A1 receptor agonist, also inhibited SCI-induced hyperalgesia. "
08/01/2008 - "Intrathecal gabapentin and R-PIA and their combination produced a dose-dependent antagonism against mechanical allodynia without severe side effects. "
01/01/2011 - "In conclusion our data shows that the neuroprotective effect of R-Pia was accompanied by a compensatory metabolic input in brain areas involved with seizures generation."
10/01/2011 - "This study showed that pretreatment with R-Pia and SCH58261 reduces seizure occurrence, although only R-Pia has neuroprotective properties. "
01/01/2001 - "Adenosine A1 receptor agonist, R(-)N6-(2-phenyl-isopropyl)adenosine (R-PIA) (0.01; 0.05; 0.1 mg/kg, i.p.) prolonged the latency to HS-induced convulsions. "
08/01/1993 - "However, seizure threshold was increased in the presence of CGS 21680 after blockade of the A1 receptor with CPX, or following activation of the A1 receptor with R-PIA or NECA. "
01/01/2005 - "Aminophylline and DPCPX but not 8pSPT also reversed the protective action of A1/A2 adenosine receptor agonist, 2-chloroadenosine (2-CADO) and selective A1 adenosine receptor agonist, R-N6-phenylisopropyloadenosine (R-PIA), against 3-NPA-evoked convulsions. "
|2.||Adenosine A1 Receptor
|3.||Glutamic Acid (Glutamate)
|5.||Purinergic P1 Receptors (Adenosine Receptor)
|6.||Morphine (MS Contin)
|7.||gamma-Aminobutyric Acid (GABA)
|9.||GABA-B Receptor Agonists